Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rob White

- PMLiVE

Severe weather warning

Shaping a market access strategy to navigate choppy local waters

- PMLiVE

Five myths about emerging markets

From strategy to access and beyond, a new look at pharma's fast-growing markets

- PMLiVE

Choosing wisely

How to make the best of emerging markets

- PMLiVE

MSF: TPP agreement could swell healthcare costs

But proponents say it will boost economic development

Tackling biosimilars – how to handle the threat to Pharma brands

Strategy Consultant Mark Assenti outlines three key points for developing a strategy to tackle the threat to Pharma brands from biosimilars.

Blue Latitude Health

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Taking a strategic approach

Janssen's Cyril Titeux on responding to the industry's pricing, access and reputational challenges

Biosimilars – the same, but different?

As more products reach European markets, US regulations are catching up with science

- PMLiVE

FDA follows WHO lead on biosimilar naming

Proposes adding suffixes to distinguish biosimilar drug names

- PMLiVE

Oncology directions

With increasingly expensive cancer drugs, what price should be paid for innovation?

- PMLiVE

Critical thinking

Assessing the Darwinian model of mutation in pharmaceutical companies

Novartis building

US ruling clears Novartis’ Zarxio but could delay other biosimilars

Federalcourt's complex ruling could have a wide-ranging impact

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links